Genentech Inc. and partners Tanox Inc. and Novartis Pharma AG said late Friday the FDA approved Xolair, a first-in-class monoclonal antibody for moderate to severe persistent asthma in adults and adolescents. (BioWorld Today)

Genentech Inc. and partners Tanox Inc. and Novartis Pharma AG said late Friday the FDA approved Xolair, a first-in-class monoclonal antibody for moderate to severe persistent asthma in adults and adolescents. (BioWorld Today)